FluoRok Raises $30M Series A to Scale HF-Free Fluorochemicals

FluoRok has raised $30m (£22.8m) in Series A funding to scale a chemical manufacturing process that eliminates hydrogen fluoride, one of the most dangerous inputs in industrial chemistry. The round, announced on 05/11/2026, brings the Oxford, UK-based company's total funding to over $57m.

The round was led by Orano Venture Fund/Supernova Invest, alongside Bidra Innovation Ventures. A long list of investors joined: Oxford Science Enterprises, BGF, GGF, Volta Energy Technologies, the University of Oxford, EverQuest Capital Partners, CPI Enterprises and WS Investments, plus angel investors. Innovate UK, the UK's innovation agency, contributed $1.3m (£1m) in grant funding on top of the equity.

What does FluoRok actually make?

FluoRok is a University of Oxford spinout led by CEO and founder Dr Gabriele Pupo. The company produces essential fluorochemicals — inputs that pharmaceutical and agrochemical makers can't easily substitute — while bypassing hydrogen fluoride (HF) entirely.

HF is highly hazardous, and its handling drives cost and risk across the fluorochemical supply chain. FluoRok's workaround is a patented mechanical activation process that runs on standard industrial equipment. Instead of requiring high-purity HF, the process uses lower-grade mined fluoride or recovered industrial waste streams as feedstock.

The output falls into two buckets: inorganic fluorides for pharmaceutical and agrochemical applications, and lithium hexafluorophosphate (LiPF₆), the dominant electrolyte salt in lithium-ion batteries.

Where does the $30m go?

The company has laid out five concrete uses for the capital:

• Supporting its transition to industrial scale
• Building demonstrator facilities for its reagents and lithium-ion battery electrolyte salts
• Expanding the team
• Validating products with customers
• Broadening commercial partnerships

That's a classic scale-up sequence: prove the process works at industrial volumes, then lock in buyers. The demonstrator facilities matter most for practitioners watching this space — they're the step between lab-scale chemistry and a bankable plant.

Why the investor list reads like a strategic map

The syndicate tells you where FluoRok expects to make money. Volta Energy Technologies points at the battery materials thesis. Orano, the French nuclear group behind the lead investor, has deep expertise in fluoride chemistry and waste streams. Oxford Science Enterprises and the University of Oxford anchor the spinout's academic roots, while BGF, GGF and CPI Enterprises bring UK growth capital and process-industry muscle.

For battery supply chains, the LiPF₆ angle is the headline. Electrolyte salts sit at the centre of every lithium-ion cell, and a production route that avoids HF while using recovered industrial waste could reshape input costs and environmental exposure for electrolyte makers.

What changes for chemical and battery buyers?

If FluoRok's demonstrators validate the process, pharma and agrochemical buyers gain a supplier whose feedstock — lower-grade mined fluoride and industrial waste — is cheaper and more flexible than HF-dependent routes. Battery makers get a second path to domestic LiPF₆ supply. The $57m total raised signals investors think the company can clear the industrial-scaling hurdle that sinks most deep-tech chemistry spinouts.

The next milestone to watch is customer validation: FluoRok says it will use the funds to prove its products with buyers, which is the step that converts a patented process into revenue.